[Infographics] Apalutamide in mHSPC: Deep and rapid PSA response correlates with longer rPFS, OS and time to CRPC

Landmark analysis of the phase III TITAN study shows that apalutamide plus ADT has resulted in UL PSA in a larger proportion of mHSPC patients than treatment with ADT alone. Furthermore, deeper and earlier UL PSA decline was associated with improved outcomes, including rPFS and OS.